Taft Chicago Pharmaceutical and Life Sciences Litigation partners Richard Ruzich and Ian Scott will present “Overview of Recent US Caselaw of Note to the Pharmaceutical Industry” at the 2025 IP Forefront Pharma Forum (IFPF) on Sept. 19 in Shanghai, China. The presenters will examine a selection of recent US legal decisions involving the Pharmaceutical sector.

For more information or to register, click here.

Ruzich is an internationally recognized patent attorney who focuses on complex patent litigation, representing generic pharmaceutical companies in ANDA litigation under the Hatch-Waxman statutory framework. An accomplished trial and appellate advocate, registered patent attorney, and a frequent lecturer and author, he is known worldwide for his legal work on behalf of his generic clients, including biosimilar sponsors. His experience covers the entire lifecycle spectrum from product selection, Paragraph IV development, and through to market entry, including at-risk launches.

Scott’s practice focuses on patent litigation, with an emphasis on pharmaceutical patent litigation under the Hatch-Waxman Act. He has extensive experience in the preparation of legal opinion in connection with planning for litigation, including opinion regarding patentability, invalidity, freedom-to-operate and priority of invention of U.S. patents and publications. Scott counsels clients in a broad array of technical fields, including pharmaceuticals and pharmaceutical formulations, chemistry and chemical processes, industrial gases and related applications, medical devices, small molecules, polymer blends and dispersions, UV absorbers, cosmetics, and golf equipment.